From Vendor to Trusted Advisor: A New B2B Playbook in Biotech | Jason C. Foster Re-Release (2/2) скачать в хорошем качестве

From Vendor to Trusted Advisor: A New B2B Playbook in Biotech | Jason C. Foster Re-Release (2/2)

Part 2 of 2 of our series with Jason C. Foster, CEO and Executive Director at Ori Biotech. We’re revisiting some of our previous episodes over the holidays this year. In this re-release, host Jon Chee sits down with Jason to cover his remarkable journey of building an international pharmaceutical company across Europe and his transition to founding Ori Biotech, a pioneering cell therapy manufacturing technology company. Jason offers candid insights into the cultural challenges of doing business across Northern and Southern Europe, the complexities of navigating different regulatory environments, and the critical importance of building mission-driven culture over purely financial incentives. He discusses how discovering cell therapy's potential to cure cancer—yet seeing patients unable to access these treatments due to cost and manufacturing limitations—compelled him to co-found Ori Biotech in 2018. Key topics covered: Building across borders: Navigating cultural differences, employment laws, and business norms while scaling a pharmaceutical company from 3 employees to 1,100+ across 37 countries in Europe and beyond ​Culture as competitive advantage: Why culture eats strategy for breakfast, lessons from Netflix's No Rules Rules, and designing companies around autonomy, mastery, and purpose rather than financial incentives ​The cell therapy revolution: Understanding personalized living medicines that turn human immune cells into cancer cures, and why 35,000+ patients have been treated but accessibility remains limited ​Commercial viability from day one: Why researchers must elevate cost and scalability alongside safety and efficacy in early development, or risk creating therapies that never reach patients ​From vendor to trusted advisor: Building Ori Biotech's ecosystem approach with servant leadership, focusing on long-term partnerships over short-term profit maximization Subscribe to the Podcast: Apple: https://podcasts.apple.com/us/podcast... Spotify: https://open.spotify.com/show/2PSL162... Youtube:    / @thebiotechstartupspodcast   Website: https://www.thebiotechstartupspodcast... --- As a TBSP listener, you can get exclusive perks through Excedr’s partner network: special savings, promotions, and more. Explore these offers today: https://www.excedr.com/partners. ---- Find Our Guest, Jason C. Foster, at these links:   / jasoncfoster   https://oribiotech.com/ Find our host, Jon Chee, at these links: LinkedIn:   / jonchee   Learn more about Excedr: LinkedIn:   / excedr   Website: https://www.excedr.com Intro & Outro Songs Created by OkKyojin, Owned by Excedr: Website: https://flow.page/kyojin Resources & Articles: How to Spin Out of Academia https://www.excedr.com/resources/how-... How VC-Backed Startups Win When They Lease https://www.excedr.com/blog/how-vc-ba... Marketing & Sales Strategies for Startups https://www.excedr.com/blog/marketing... Companies, Universities, & People mentioned: Farlan Veraitch   / farlan-singh-veraitch-a677112   Reed Hastings   / reedhastings   Dan Pink   / danielpink   Timestamps: 00:00 Intro 01:08 Touching Down in London and Cultural Adjustments 04:32 Mentorship and Navigating European Business 07:07 The Journey to IPO at the LSE 11:46 Lessons in Entrepreneurship and Finding Your Role 16:19 The Power of Culture in Building Companies 21:31 Entering the Venture Ecosystem and Discovering Cell Therapy 28:51 Founding Ori Biotech and Building From Scratch 35:37 Commercial Viability and Downstream Thinking in Drug Development 42:16 Go-to-Market Approach and Building Credibility 58:52 What's Next for Ori Biotech 01:01:51 Shout-Outs and Closing Advice 01:07:20 Outro #CellTherapy #BiotechStartups #ManufacturingInnovation #StartupCulture #PersonalizedMedicine The Biotech Startups Podcast is powered by Excedr—helping life science startups accelerate R&D and commercialization with founder-friendly equipment leasing.